Phase 3 trial results for rolapitant, a novel NK-1 receptor antagonist, in the prevention of chemotherapy-induced nausea and vomiting (CINV) in subjects receiving moderately emetogenic chemotherapy (MEC)

被引：6
|
作者：
Schnadig, Ian D.
Modiano, Manuel R.
Poma, Allen
Hedley, Mary Lynne
Martell, Robert E.
Schwartzberg, Lee Steven
机构：
[1] Compass Oncol, Portland, OR USA
[2] US Oncol Network, Portland, OR USA
[3] Arizona Clin Res Ctr, Tucson, AZ USA
[4] TESARO Inc, Waltham, MA USA
[5] Tufts Med Ctr, Div Hematol Oncol, Boston, MA USA
[6] Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.9633
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9633
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [41] Aprepitant for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy
    Takako Inoue
    Madoka Kimura
    Junji Uchida
    Kazumi Nishino
    Toru Kumagai
    Junko Taniguchi
    Fumio Imamura
    International Journal of Clinical Oncology, 2017, 22 : 600 - 604
  • [42] Aprepitant for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy
    Inoue, Takako
    Kimura, Madoka
    Uchida, Junji
    Nishino, Kazumi
    Kumagai, Toru
    Taniguchi, Junko
    Imamura, Fumio
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2017, 22 (03) : 600 - 604
  • [43] Efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC)
    Aapro, M.
    Rossi, G.
    Rizzi, G.
    Borroni, M. E.
    Lorusso, V.
    Karthaus, M.
    Grunberg, S.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S266 - S266
  • [44] Efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with gastrointestinal and colorectal cancers
    Navari, R.
    Jordan, K.
    Rapoport, B. L.
    Schnadig, I.
    Chasen, M.
    Arora, S.
    Powers, D.
    Schwartzberg, L.
    ANNALS OF ONCOLOGY, 2016, 27
  • [45] Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial
    Ralph Boccia
    Steven Grunberg
    Edwin Franco-Gonzales
    Edward Rubenstein
    Daniel Voisin
    Supportive Care in Cancer, 2013, 21 : 1453 - 1460
  • [46] Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial
    Boccia, Ralph
    Grunberg, Steven
    Franco-Gonzales, Edwin
    Rubenstein, Edward
    Voisin, Daniel
    SUPPORTIVE CARE IN CANCER, 2013, 21 (05) : 1453 - 1460
  • [47] An oral NK1 antagonist for the prevention of nausea and vomiting induced by highly emetogenic chemotherapy
    Pendergrass, K
    Hargreaves, R
    Petty, KJ
    Carides, AD
    Evans, JK
    Horgan, KJ
    DRUGS OF TODAY, 2004, 40 (10) : 853 - 863
  • [48] A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy
    Zelek, Laurent
    Debourdeau, Philippe
    Bourgeois, Hugues
    Wagner, Jean Philippe
    Brocard, Fabien
    Lefeuvre-Plesse, Claudia
    Chauffert, Bruno
    Leheurteur, Marianne
    Bachet, Jean-Baptiste
    Simon, Helene
    Mayeur, Didier
    Scotte, Florian
    ONCOLOGIST, 2021, 26 (10): : E1870 - E1879
  • [49] Phase 3 trial of APF530 versus palonosetron (PALO) in preventing chemotherapy-induced nausea and vomiting (CINV): Efficacy in breast cancer patients (pts) receiving moderately (MEC) or highly (HEC) emetogenic chemotherapy.
    Boccia, Ralph V.
    Cooper, William
    O'Boyle, Erin
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [50] Safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving breast cancer resistant protein (BCRP) substrate chemotherapy agents
    Schwartzberg, L.
    Jordan, K.
    Rapoport, B. L.
    Schnadig, I.
    Chasen, M.
    Arora, S.
    Barbour, S.
    Powers, D.
    Navari, R.
    ANNALS OF ONCOLOGY, 2016, 27
12345